Grown Rogue International (GRUSF) Convertible Debt (2014 - 2026)
Grown Rogue International's (GRUSF) quarterly Convertible Debt came in at $2.8 million in Q1 2026, up 139.36% year-on-year from $1.2 million in Q1 2025, and up 7.36% quarter-over-quarter from $2.6 million in Q4 2025.
Grown Rogue International (GRUSF) Convertible Debt (2014 - 2026) Analysis & Trends
Grown Rogue International's Convertible Debt history runs 12 years deep, the most recent figure standing at $2.8 million for Q1 2026.
- On a quarterly basis, Convertible Debt rose 139.36% year-over-year to $2.8 million in Q1 2026; TTM through Mar 2026 was $2.8 million, a 139.36% increase from a year earlier, with the FY2025 full-year figure at $2.6 million, up 1031.51% from the prior year.
- Convertible Debt grew to $2.8 million in Q1 2026 per GRUSF's latest filing, from $2.6 million in the prior quarter.
- Across five years, Convertible Debt topped out at $1625.2 billion in Q3 2025 and bottomed at $227680.0 in Q4 2024.
- The 5-year median for Convertible Debt is $1.2 million (2023), against an average of $116.1 billion.
- Across the five-year window, Convertible Debt sank 60.28% in 2024 and soared 396939409.31% in 2025, its largest moves.
- Year by year, Convertible Debt stood at $1.8 million in 2022, then plunged by 67.61% to $573200.7 in 2023, then sank by 60.28% to $227680.0 in 2024, then surged by 1031.51% to $2.6 million in 2025, then advanced by 7.36% to $2.8 million in 2026.
- Per Business Quant, the three latest GRUSF Convertible Debt figures stand at $2.8 million (Q1 2026), $2.6 million (Q4 2025), and $1625.2 billion (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Grown Rogue International | 99.97 Mn | 92.67 Mn | 3.96 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.77 Mn |
| Dec 31, 2025 | 2.58 Mn |
| Sep 30, 2025 | 1,625.16 Bn |
| Jun 30, 2025 | 1.06 Mn |
| Mar 31, 2025 | 1.16 Mn |
| Dec 31, 2024 | 227,680.00 |
| Sep 30, 2024 | 409,421.33 |
| Jun 30, 2024 | 445,212.68 |
| Mar 31, 2024 | 838,332.00 |
| Dec 31, 2023 | 573,200.67 |
| Oct 31, 2023 | 1.29 Mn |
| Apr 30, 2023 | 1.93 Mn |
| Jan 31, 2023 | 1.96 Mn |
| Oct 31, 2022 | 1.77 Mn |
| Oct 31, 2021 | 843,900.00 |
| Apr 30, 2021 | 311,272.00 |
| Jan 31, 2021 | 329,166.00 |
| Oct 31, 2020 | 46,099.00 |
| Jul 31, 2020 | 315,139.00 |
| Apr 30, 2020 | 50,000.00 |